These peptides are inhibitors of a protein called myostatin. Myostatin is secreted by muscle cells and acts to essentially block the development of new muscle fibers and, thus, the development of lean muscle mass. In fact, individuals who have mutations in the gene coding for this protein have significantly more muscle mass and enhanced strength. The administration of follastatin peptides can generate enhanced muscle mass and strength, and has been found especially useful in patients suffering from muscle-wasting diseases or who have difficulty gaining muscle.

For example, insufficient protein or calories can cause IGF-1 to plummet, while ample calories can cause IGF-1 to increase. For example, one study of women who fed with excess calories over and above their normal metabolic rate noted a 19% increase in IGF-1 after two weeks of overfeeding, with 46% of the weight gain from  lean mass and 54% from bodyfat. Fasting insulin doubled in these women, and testosterone levels also significantly increased.

A SARM (an acronym for "Selective Androgen Receptor Modulator") is a drug that is chemically similar to anabolic steroids but with reduced androgenic properties. The main advantages SARMs have over anabolic steroids are androgen-receptor specificity, tissue selectivity, and reduced side effects. SARMs also have the ability to differentiate between anabolic and androgenic activities, whereas steroids do not.
When combined with the other IGF-1 and growth hormone boosting strategies you’ve just discovered – such as eating adequate calories, heavy weight training, 7-9 hours of sleep per 24 hour cycle, adequate mineral intake and moderation of alcohol intake – these additional strategies will ensure you get all the anabolic effects of IGF-1 and growth hormone without having to resort to needles, syringes, prescriptions, online pharmacies and potentially dangerous self-experimentation.
Since GHRP-6 influences natural GH release, rules for its administration are similar to those when administering GH itself, i.e. do not have the dose within a 2 hour window after a meal, and/or wait 30 minutes till eating after dosing, due to any endogenous insulin release from the meal possibly stunting the release of natural GH and its uptake by the relevant cells.
The prescription form of IGF-1 most often injected is “mecasermin”, which goes by the trade name Increlex. Manufactured using recombinant DNA technology, mecasermin is clinically used to treat IGF-1 deficiency and stunted growth. It is also prescribed to patients who have developed antibody resistance to normal growth hormone therapy. Increlex is actually identical to natural IGF-1, meaning that it has the identical 70 amino acid sequence of IGF-1 that the body produces. In other words, it’s not some kind of growth hormone “precursor”. It’s just straight up IGF-1.
In June 2007, the NDPSC decided to extend the exemption from the limit on paracetamol combinations being allowed as general sale products to include phenylephrine (as long as it also qualified as exempt from scheduling through the phenylephrine entries). At that time, the NDPSC considered that the safety profile of these substances was such that allowing a fixed combination to be unscheduled was reasonable.
Because the ligands of most GPCRs are unknown, assays for their activity generally have no positive controls. GHS-R, however, was known to bind several artificial ligands, such as GHRP-6 or hexarelin, providing a convenient positive control for constructing the assay system used to search for the endogenous ligand. A cultured cell line expressing the GHS-R was established and used to identify tissue extracts that could stimulate the GHS-R, as monitored by increases in intracellular Ca2+ levels. After screening several tissues, very strong activity by an endogenous ligand was unexpectedly found in stomach extracts (). The ligand was finally purified by reversed-phase HPLC (RP-HPLC) and named as ghrelin. The name “ghrelin” is based on “ghre,” a word root in Proto-Indo-European languages for “grow,” in reference to its ability to stimulate GH release. Ghrelin is a 28 amino acid peptide in which the serine 3 (Ser3) is n-octanoylated and this modification is essential for the activity of ghrelin (Fig. 2). Ghrelin is the first known case of a peptide hormone modified by a fatty acid. Rat and human ghrelins differ in only two amino acid residues. There is no structural homology between ghrelin and peptide GHSs such as GHRP-6 or hexarelin.
The scheduling of paracetamol and caffeine when combined in a compound analgesic as the only two active ingredients was amended from Schedule 4 to Schedule 2 by the NDPSC at its 50th Meeting in June 2007. Evidence reviewed by the Committee at that time conclusively demonstrated that the key ingredient in terms of analgesic overuse and nephropathy was phenacetin and not caffeine. It was agreed that the indications for use, safety profile and potential for misuse met the criteria for a Schedule 2 medicine.
CJC1295 is a 30 amino acid peptide, which primarily functions as a growth hormone releasing hormone analogue (mimicking the effect of GHRH). It was initially invented to treat deep fat deposits in people, because it is known that having an increase in our own growth hormone levels will target this. It stimulates production of our own growth hormone from the pituitary gland.
Figure 3: Impact of GHRP-6 treatment on wound angiogenesis. Anti-CD31 immunolabeling for mature endothelial cells. Images are representative of (a) vehicle (1% CMC)-treated wounds; (b) GHRP-6-treated wounds. No histological differences were detected between the groups in relation to the number of neovessels, their structure, distribution, organization, or CD31 positivity.
Figure 2: GHRP-6-mediated response to inflammation. Images are representative of (a) wounds topically treated with vehicle (1% CMC); (b) wounds topically treated with GHRP-6. GHRP-6 treatment reduced the inflammatory infiltration of mononuclear basophilic round cells. In contrast, CMC-treated wounds exhibit a physiologically normal infiltration, which matches the biological stage of the wound. 5 μm section, H/E, 20x magnification.
You’re no doubt taking it for the fairy tale positive side effects, which have already been outlined, but like any caper about something enchanted, the magic comes with a price. For GHRP6 these can include flu-like symptoms, joint aches, headaches and water retention. Prolonged use can give you a tingling feeling in your skin than can also lead to a loss of sensitivity to touch. Yeah, you don’t want it down there. Fortunately, this is often in rare cases and when you consider even garden-variety paracetamol can dish out hives, diarrhoea and nausea then by comparison these aren’t huge risk factors. The biggest drawback is that it has a meagre half-life of 15-60 minutes, which means you have to take it daily for it to be effective, with the primary method of administration being a big ole fat needle. So the idea of turning the glutes into something that resembles nanna’s pincushion may deter pretty much all-conscientious pain objectors.